Base de dados : MEDLINE
Pesquisa : D12.776.260.655.500.100 [Categoria DeCS]
Referências encontradas : 790 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 79 ir para página                         

  1 / 790 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28935584
[Au] Autor:Liu C; Jia X; Zou Z; Wang X; Wang Y; Zhang Z
[Ad] Endereço:Key Laboratory of Healthy Mariculture for the East China Sea, Ministry of Agriculture, Fisheries College, Jimei University, Xiamen 361021, China.
[Ti] Título:VIH from the mud crab is specifically expressed in the eyestalk and potentially regulated by transactivator of Sox9/Oct4/Oct1.
[So] Source:Gen Comp Endocrinol;255:1-11, 2018 Jan 01.
[Is] ISSN:1095-6840
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Vitellogenesis-inhibiting hormone (VIH) is known to regulate ovarian maturation by suppressing the synthesis of vitellogenin (Vtg) in crustaceans, which belongs to a member of crustacean hyperglycemic hormone (CHH) family synthesized and secreted from the X-organ/sinus gland complex of eyestalks. In this study, the cDNA, genomic DNA (gDNA) and the 5'-upstream regulatory (promoter region) sequences of VIH gene were obtained by conventional PCR, genome walker and tail-PCR techniques according to our transcriptomic database of Scylla paramamosain. The full-length cDNA of SpVIH is 634bp including 105bp 5'UTR, 151bp 3'UTR and 378bp ORF that encodes a peptide of 125 amino acids. The full length gDNA of SpVIH is 790bp containing two exons and one intron. The 5'-flanking promoter regions of SpVIH we isolated are 3070bp from the translation initiation (ATG) and 2398bp from the predicted transcription initiation (A), which consists of putative core promoter region and multiple potential transcription factor binding sites. SpVIH was only expressed in eyestalk. The expression level of SpVIH in eyestalk of female crab decreased gradually along with the development of ovary. As there is not cell line of crabs available, we chose the mature transfection system HEK293FT cell lines to explore the mechanism of transcription regulation of SpVIH in crabs. Sequential deletion assays using luciferase reporter gene in HEK293FT cells revealed that the possible promoter activity regions (including positive and negative transcription factors binding sites simultaneously) presented between pSpVIH-4 and pSpVIH-6. In order to further identify the crucial transcription factors binding site in this region, the site-directed mutagenesis of Sox9/Oct4/Oct1 binding site of pSpVIH-4 was created. The results demonstrated that the transcriptional activity of pSpVIH-4â–³ decreased significantly (p<0.05). Thus, it is reasonable to deduce that the Sox9/Oct4/Oct1 may be the essential positive transcription factors which regulate the expression of SpVIH.
[Mh] Termos MeSH primário: Braquiúros/metabolismo
Proteínas de Transporte/metabolismo
Olho/metabolismo
Hormônios de Invertebrado/metabolismo
Fator 1 de Transcrição de Octâmero/metabolismo
Fator 3 de Transcrição de Octâmero/metabolismo
Fatores de Transcrição SOX9/metabolismo
Transativadores/metabolismo
[Mh] Termos MeSH secundário: Região 5'-Flanqueadora/genética
Sequência de Aminoácidos
Animais
Sequência de Bases
Proteínas de Transporte/química
Proteínas de Transporte/genética
DNA Complementar/genética
Feminino
Regulação da Expressão Gênica no Desenvolvimento
Células HEK293
Seres Humanos
Hormônios de Invertebrado/química
Hormônios de Invertebrado/genética
Mutação/genética
Ovário/embriologia
Ovário/metabolismo
Filogenia
Regiões Promotoras Genéticas/genética
Análise de Sequência de DNA
Transgenes
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Carrier Proteins); 0 (DNA, Complementary); 0 (Invertebrate Hormones); 0 (Octamer Transcription Factor-1); 0 (Octamer Transcription Factor-3); 0 (SOX9 Transcription Factor); 0 (Trans-Activators); 138360-48-2 (vitellogenesis inhibiting hormone)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180216
[Lr] Data última revisão:
180216
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170923
[St] Status:MEDLINE


  2 / 790 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28470102
[Au] Autor:Balyan R; Zhang X; Chidambaran V; Martin LJ; Mizuno T; Fukuda T; Vinks AA; Sadhasivam S
[Ad] Endereço:Department of Anesthesia, College of Medicine, University of Cincinnati, Cincinnati, OH 45229, USA.
[Ti] Título:OCT1 genetic variants are associated with postoperative morphine-related adverse effects in children.
[So] Source:Pharmacogenomics;18(7):621-629, 2017 May.
[Is] ISSN:1744-8042
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:AIM: Large interindividual variability in morphine pharmacokinetics (PK) could contribute to variability in morphine analgesia and adverse events. Respiratory depression (RD) and postoperative nausea and vomiting (PONV) are significant adverse drug response of intravenous morphine in the perioperative setting limiting its efficacy in achieving adequate surgical pain relief. OCT1 is a transporter in the liver that transports morphine from the bloodstream into hepatocytes. Earlier we reported association of genetic polymorphisms in OCT1 with morphine PK, and lower morphine clearance in Caucasian children as compared with African-American (AA) children. The aim of this study is to identify the association between common OCT1 genotypes affecting morphine's PK and clinically important postoperative morphine-related adverse outcomes. METHODS: After obtaining institutional review board (IRB) approval and informed consents, 311 children ages 6-15 years, American Society of Anesthesiologists' physical status 1 or 2 scheduled for tonsillectomy who received standard anesthetic, surgical and postoperative care were recruited. Clinical data collected included postoperative pain scores, total opioid use, incidence of PONV and RD. Four nonsynonymous SNPs of the OCT1 gene (rs12208357, rs34130495, rs72552763 and rs34059508) in each patient were genotyped using commercially available TaqMan assays. We investigated the genetic association of OCT1 with incidences of postoperative RD and PONV. RESULTS: Caucasian and AA children differed significantly in the incidence of obstructive sleep apnea (p < 0.001) and total morphine use (p = 0.028). There were incidences of prolonged post anesthesia care unit stay in 7% of Caucasian children, while no such incidences were observed for AA children (p = 0.05). OCT1 polymorphism rs12208357 was associated with high incidences of PONV and PONV leading to prolonged post anesthesia care unit stay (p < 0.05). A significant association was also found between rs72552763 GAT deletion and high incidence of RD (p = 0.007). CONCLUSION: Children with certain OCT1 genotypes are associated with higher risk for RD and PONV following morphine administration leading to prolonged hospital stay. The OCT1 transporters' effects on morphine's PK could explain this association.
[Mh] Termos MeSH primário: Afroamericanos/genética
Grupo com Ancestrais do Continente Europeu/genética
Morfina/efeitos adversos
Fator 1 de Transcrição de Octâmero/genética
Variantes Farmacogenômicos/genética
Complicações Pós-Operatórias/genética
[Mh] Termos MeSH secundário: Adolescente
Analgésicos Opioides/administração & dosagem
Analgésicos Opioides/efeitos adversos
Criança
Feminino
Seres Humanos
Masculino
Morfina/administração & dosagem
Dor Pós-Operatória/genética
Dor Pós-Operatória/prevenção & controle
Complicações Pós-Operatórias/induzido quimicamente
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Analgesics, Opioid); 0 (Octamer Transcription Factor-1); 0 (POU2F1 protein, human); 76I7G6D29C (Morphine)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180112
[Lr] Data última revisão:
180112
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE
[do] DOI:10.2217/pgs-2017-0002


  3 / 790 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28542436
[Au] Autor:Boubriak II; Malhas AN; Drozdz MM; Pytowski L; Vaux DJ
[Ad] Endereço:Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom.
[Ti] Título:Stress-induced release of Oct-1 from the nuclear envelope is mediated by JNK phosphorylation of lamin B1.
[So] Source:PLoS One;12(5):e0177990, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The nuclear lamina can bind and sequester transcription factors (TFs), a function lost if the lamina is abnormal, with missing or mutant lamin proteins. We now show that TF sequestration is not all-or-nothing, but a dynamic physiological response to external signals. We show that the binding of the ubiquitous TF, Oct-1, to lamin B1 was reversed under conditions of cellular stress caused, inter alia, by the chemical methylating agent methylmethanesulfonate (MMS). A search for lamin B1 post-translational modifications that might mediate changes in Oct-1 binding using kinase inhibitors uncovered a role for c-Jun N-terminal kinase (JNK). Phosphoproteomic and site-directed mutagenesis analyses of lamin B1 isolated from control and MMS-treated nuclei identified T575 as a JNK site phosphorylated after stress. A new phospho-T575 specific anti-peptide antibody confirmed increased interphase cellular T575 phosphorylation after cell exposure to certain stress conditions, enabling us to conclude that lamin B1 acts as an interphase kinase target, releasing Oct-1 to execute a protective response to stress.
[Mh] Termos MeSH primário: Proteínas Quinases JNK Ativadas por Mitógeno/metabolismo
Lamina Tipo B/metabolismo
Membrana Nuclear/metabolismo
Fator 1 de Transcrição de Octâmero/secreção
Estresse Fisiológico/fisiologia
[Mh] Termos MeSH secundário: Proteínas de Ciclo Celular/biossíntese
Linhagem Celular Tumoral
Células HeLa
Seres Humanos
Lamina Tipo A/metabolismo
Metanossulfonato de Metila/farmacologia
Mutagênese Sítio-Dirigida
Proteínas Nucleares/biossíntese
Fosforilação
Ligação Proteica
Proteína de Ligação a Elemento Regulador de Esterol 1/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cell Cycle Proteins); 0 (GADD45A protein, human); 0 (Lamin Type A); 0 (Lamin Type B); 0 (Nuclear Proteins); 0 (Octamer Transcription Factor-1); 0 (POU2F1 protein, human); 0 (SREBF1 protein, human); 0 (Sterol Regulatory Element Binding Protein 1); 0 (lamin B1); AT5C31J09G (Methyl Methanesulfonate); EC 2.7.11.24 (JNK Mitogen-Activated Protein Kinases)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170918
[Lr] Data última revisão:
170918
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170526
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0177990


  4 / 790 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28380657
[Au] Autor:Sundelin E; Gormsen LC; Jensen JB; Vendelbo MH; Jakobsen S; Munk OL; Christensen M; Brøsen K; Frøkiaer J; Jessen N
[Ad] Endereço:Research Laboratory for Biochemical Pathology, Department of Clinical Medicine, Aarhus University Hospital, Denmark.
[Ti] Título:Genetic Polymorphisms in Organic Cation Transporter 1 Attenuates Hepatic Metformin Exposure in Humans.
[So] Source:Clin Pharmacol Ther;102(5):841-848, 2017 Nov.
[Is] ISSN:1532-6535
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Metformin has been used successfully to treat type 2 diabetes for decades. However, the efficacy of the drug varies considerably from patient to patient and this may in part be due to its pharmacokinetic properties. The aim of this study was to examine if common polymorphisms in SLC22A1, encoding the transporter protein OCT1, affect the hepatic distribution of metformin in humans. We performed noninvasive C-metformin positron emission tomography (PET)/computed tomography (CT) to determine hepatic exposure in 12 subjects genotyped for variants in SLC22A1. Hepatic distribution of metformin was significantly reduced after oral intake in carriers of M420del and R61C variants in SLC22A1 without being associated with changes in circulating levels of metformin. Our data show that genetic polymorphisms in transporter proteins cause variation in hepatic exposure to metformin, and it demonstrates the application of novel imaging techniques to investigate pharmacogenetic properties in humans.
[Mh] Termos MeSH primário: Hipoglicemiantes/administração & dosagem
Fígado/efeitos dos fármacos
Metformina/administração & dosagem
Fator 1 de Transcrição de Octâmero/genética
Polimorfismo de Nucleotídeo Único/genética
[Mh] Termos MeSH secundário: Adulto
Feminino
Seres Humanos
Hipoglicemiantes/metabolismo
Injeções Intravenosas
Fígado/diagnóstico por imagem
Fígado/metabolismo
Masculino
Metformina/metabolismo
Meia-Idade
Tomografia por Emissão de Pósitrons/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hypoglycemic Agents); 0 (Octamer Transcription Factor-1); 0 (POU2F1 protein, human); 9100L32L2N (Metformin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171020
[Lr] Data última revisão:
171020
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170406
[St] Status:MEDLINE
[do] DOI:10.1002/cpt.701


  5 / 790 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28341486
[Au] Autor:Dasgupta N; Thakur BK; Ta A; Das S; Banik G; Das S
[Ad] Endereço:National Institute of Cholera & Enteric Diseases (ICMR), Clinical Medicine, P-33, CIT Road, Scheme-XM, Beliaghata, Kolkata 700010, West Bengal, India; Sanford Burnham Prebys Medical Discovery Institute, 10901 N Torrey Pines Road, La Jolla, CA 92037, United States.
[Ti] Título:Polo-like kinase 1 expression is suppressed by CCAAT/enhancer-binding protein α to mediate colon carcinoma cell differentiation and apoptosis.
[So] Source:Biochim Biophys Acta;1861(7):1777-1787, 2017 07.
[Is] ISSN:0006-3002
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Human polo-like kinase 1 (PLK1), a highly conserved serine/threonine kinase is a key player in several essential cell-cycle events. PLK1 is considered an oncogene and its overexpression often correlates with poor prognosis of cancers, including colorectal cancer (CRC). However, regulation of PLK1 expression in colorectal cells was never studied earlier and it is currently unknown if PLK1 regulates differentiation and apoptosis of CRC. METHODS: PLK1 expression was analyzed by real-time PCR and western blotting. Transcriptional regulation was studied by reporter assay, gene knock-down, EMSA and ChIP. RESULTS: PLK1 expression was down-regulated during butyrate-induced differentiation of HT-29 and other CRC cells. Also, PLK1 down-regulation mediated the role of butyrate in CRC differentiation and apoptosis. We report here a novel transcriptional regulation of PLK1 by butyrate. Transcription factors CCAAT/enhancer-binding protein α (C/EBPα) and Oct-1 share an overlapping binding site over the PLK1 promoter. Elevated levels of C/EBPα by butyrate treatment of CRC cells competed out the activator protein Oct-1 from binding to the PLK1 promoter and sequestered it. Binding of C/EBPα was associated with increased deacetylation near the transcription start site (TSS) of the PLK1 promoter, which abrogated transcription through reduced recruitment of RNA polymerase II. We also found a synergistic role between the synthetic PLK1-inhibitor SBE13 and butyrate on the apoptosis of CRC cells. CONCLUSION: This study offered a novel p53-independent regulation of PLK1 during CRC differentiation and apoptosis. GENERAL SIGNIFICANCE: Down-regulation of PLK1 is one of the mechanisms underlying the anti-cancer role of dietary fibre-derived butyrate in CRC.
[Mh] Termos MeSH primário: Apoptose
Proteína alfa Estimuladora de Ligação a CCAAT/fisiologia
Proteínas de Ciclo Celular/genética
Neoplasias Colorretais/patologia
Proteínas Serina-Treonina Quinases/genética
Proteínas Proto-Oncogênicas/genética
[Mh] Termos MeSH secundário: Apoptose/efeitos dos fármacos
Benzilaminas/farmacologia
Butiratos/farmacologia
Proteínas de Ciclo Celular/antagonistas & inibidores
Diferenciação Celular/efeitos dos fármacos
Linhagem Celular Tumoral
Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos
Seres Humanos
Fator 1 de Transcrição de Octâmero/fisiologia
Proteínas Serina-Treonina Quinases/antagonistas & inibidores
Proteínas Proto-Oncogênicas/antagonistas & inibidores
Piridinas/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Benzylamines); 0 (Butyrates); 0 (CCAAT-Enhancer-Binding Protein-alpha); 0 (Cell Cycle Proteins); 0 (Octamer Transcription Factor-1); 0 (Proto-Oncogene Proteins); 0 (Pyridines); 0 (SBE13 compound); EC 2.7.11.1 (Protein-Serine-Threonine Kinases); EC 2.7.11.1 (polo-like kinase 1)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171103
[Lr] Data última revisão:
171103
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170326
[St] Status:MEDLINE


  6 / 790 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28290268
[Au] Autor:Cosenza G; Iannaccone M; Pico BA; Gallo D; Capparelli R; Pauciullo A
[Ad] Endereço:Department of Agricultural Sciences,University of Naples 'Federico II',Portici (NA),Italy.
[Ti] Título:Molecular characterisation, genetic variability and detection of a functional polymorphism influencing the promoter activity of OXT gene in goat and sheep.
[So] Source:J Dairy Res;84(2):165-169, 2017 May.
[Is] ISSN:1469-7629
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The purpose of the study described in this Research Communication was to report the full characterisation of the goat and sheep oxytocin-neurophysin I gene (OXT), their promoters and amino acid sequences. Using the genomic DNA as template, we sequenced and compared the whole OXT gene (3 exons), plus 958/960 nucleotides at the 5' flanking region and 478/477 nucleotides at the 3' flanking region, in 46 sheep and 24 goats belonging to different breeds/genetic types reared in Italy, Greece and Germany. The comparison of the obtained sequences showed a high degree of genetic variability at these loci. In particular, we focused on the SNP g.438T > C as possible example of trans-specific polymorphism. This SNP alters a putative binding site of the transcription factor Oct-1. The set-up of a luciferase assay confirmed that the C variant of this SNP negatively affects the promoter activity of the sheep OXT gene. The results of this study suggest that the SNP g.438T > C might be useful to promote association studies with traits/physiological processes controlled by this hormone.
[Mh] Termos MeSH primário: Cabras/genética
Neurofisinas/genética
Ocitocina/genética
Polimorfismo de Nucleotídeo Único/genética
Regiões Promotoras Genéticas/genética
Ovinos/genética
[Mh] Termos MeSH secundário: Sequência de Aminoácidos
Animais
Sítios de Ligação/genética
Variação Genética/genética
Alemanha
Grécia
Itália
Neurofisinas/química
Fator 1 de Transcrição de Octâmero/metabolismo
Ocitocina/química
Polimorfismo Genético/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Neurophysins); 0 (Octamer Transcription Factor-1); 50-56-6 (Oxytocin)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170828
[Lr] Data última revisão:
170828
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170315
[St] Status:MEDLINE
[do] DOI:10.1017/S0022029917000097


  7 / 790 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28289867
[Au] Autor:Galeotti L; Ceccherini F; Domingo D; Laurino M; Polillo M; Di Paolo A; Baratè C; Fava C; D'Avolio A; Cervetti G; Guerrini F; Fontanelli G; Ciabatti E; Grassi S; Arrigoni E; Danesi R; Petrini M; Cornolti F; Saglio G; Galimberti S
[Ad] Endereço:Phymtech Srl, Via Giuntini 63, Navacchio, 56023, Pisa, Italy.
[Ti] Título:Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia.
[So] Source:Cancer Chemother Pharmacol;79(4):767-773, 2017 Apr.
[Is] ISSN:1432-0843
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:PURPOSE: The present study was aimed at investigating whether imatinib pharmacogenetics is related to its pharmacodynamics in patients affected by chronic myeloid leukemia. METHODS: Through a procedure based on a sequence of classical statistics methods, we investigated the possible relationships between treatment efficacy/tolerability and combinations of time-independent variables as gender and genetic covariates in the form of single nucleotide polymorphisms (SNPs) or combinations thereof. Moreover, since the drug tolerability has a strong incidence on the discontinuation of the therapy, we investigated whether the time of manifestation of the most frequent toxic effects can be related to time-independent patients' characteristics or not. RESULTS: We found that a combination of two polymorphisms, namely hOCT1 c.480C>G (rs683369) and ABCB1 c.3435C>T (rs1045642), seems to play the role of predictor for imatinib in both efficacy and toxicity. Furthermore, the time of manifestation of edema toxicity is found to be associated to a combination of gender and ABCB1 c.3435C>T, whereas the time of manifestation of cramp toxicity appears related to gender. CONCLUSIONS: The novelty of this study is dual: the achievement of results that potentially have a significant clinical interest and the demonstration that the adoption of composed covariates may represent a unique tool to study different aspects of the treatment with imatinib.
[Mh] Termos MeSH primário: Antineoplásicos/efeitos adversos
Antineoplásicos/uso terapêutico
Mesilato de Imatinib/efeitos adversos
Mesilato de Imatinib/uso terapêutico
Leucemia Mielogênica Crônica BCR-ABL Positiva/tratamento farmacológico
Leucemia Mielogênica Crônica BCR-ABL Positiva/genética
Fator 1 de Transcrição de Octâmero/genética
[Mh] Termos MeSH secundário: Subfamília B de Transportador de Cassetes de Ligação de ATP/genética
Adulto
Idoso
Idoso de 80 Anos ou mais
Edema/induzido quimicamente
Edema/genética
Análise Fatorial
Feminino
Genótipo
Seres Humanos
Masculino
Meia-Idade
Cãibra Muscular/induzido quimicamente
Cãibra Muscular/genética
Farmacogenética
Polimorfismo Genético
Prognóstico
Caracteres Sexuais
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (ABCB1 protein, human); 0 (ATP Binding Cassette Transporter, Sub-Family B); 0 (Antineoplastic Agents); 0 (Octamer Transcription Factor-1); 0 (POU2F1 protein, human); 8A1O1M485B (Imatinib Mesylate)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170315
[St] Status:MEDLINE
[do] DOI:10.1007/s00280-017-3271-3


  8 / 790 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28286932
[Au] Autor:Ben Hassine I; Gharbi H; Soltani I; Teber M; Farrah A; Ben Hadj Othman H; Amouri H; Bellaaj H; Lakhal RB; Romdhane NB; Abbes S; Menif S
[Ad] Endereço:Laboratory of Molecular and Cellular Hematology, Pasteur Institute of Tunis, University of Tunis El Manar, Tunis, Tunisia. benhassine.islem@gmail.com.
[Ti] Título:hOCT1 gene expression predict for optimal response to Imatinib in Tunisian patients with chronic myeloid leukemia.
[So] Source:Cancer Chemother Pharmacol;79(4):737-745, 2017 Apr.
[Is] ISSN:1432-0843
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Imatinib mesylate (IM) is considered as a highly effective therapy for chronic myeloid leukemia (CML) patients. However, a minority of patients fail to achieve optimal response due to impaired bioavailability of IM. The human organic cation transporter 1 (OCT1; SLC22A1) has been reported to be the main influx transporter involved in IM uptake into CML cells. Genetic variants and/or hOCT1 expression changes may influence IM response. In this study, we aimed to investigate the impact of both hOCT1 polymorphisms located in exon 7 and hOCT1 mRNA levels on the clinical outcome in CML patients. METHODS: hOCT1 expression profile was determined using the quantitative real-time polymerase chain reaction in 69 CML patients treated with IM (35 responders to IM patients and 34 IM-resistant patients), while genotyping of 69 cases and 51 controls for hOCT1 polymorphisms was performed by direct sequencing after amplification of exon7. RESULTS: Our results showed that the hOCT1 gene was significantly downregulated in the samples of the IM-resistant group when compared with the IM-responder group (p = 0.0211). Moreover, sequencing data show an association in all cases between the SNP 408V>M (g.1222G>A) and an intronic 8 bp (base pairs) insertion of GTAAGTTG (rs36056065) at the 3' end of exon 7. The genotype and allele distribution of the different SNPs did not differ significantly between the two groups of patients. CONCLUSIONS: hOCT1 mRNA expression may serve as a clinical biomarker of response to imatinib and could be useful to predict IM therapy outcome of CML patients.
[Mh] Termos MeSH primário: Antineoplásicos/uso terapêutico
Mesilato de Imatinib/uso terapêutico
Leucemia Mielogênica Crônica BCR-ABL Positiva/tratamento farmacológico
Leucemia Mielogênica Crônica BCR-ABL Positiva/genética
Fator 1 de Transcrição de Octâmero/biossíntese
Inibidores de Proteínas Quinases/uso terapêutico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Alelos
Biomarcadores Tumorais/sangue
Regulação para Baixo/efeitos dos fármacos
Éxons/genética
Feminino
Genótipo
Seres Humanos
Masculino
Meia-Idade
Fator 1 de Transcrição de Octâmero/genética
Polimorfismo Genético/genética
Polimorfismo de Nucleotídeo Único/genética
RNA Mensageiro/biossíntese
RNA Mensageiro/genética
Tunísia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Biomarkers, Tumor); 0 (Octamer Transcription Factor-1); 0 (POU2F1 protein, human); 0 (Protein Kinase Inhibitors); 0 (RNA, Messenger); 8A1O1M485B (Imatinib Mesylate)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170613
[Lr] Data última revisão:
170613
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170314
[St] Status:MEDLINE
[do] DOI:10.1007/s00280-017-3266-0


  9 / 790 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28199510
[Au] Autor:Akhmedov A; Camici GG; Reiner MF; Bonetti NR; Costantino S; Holy EW; Spescha RD; Stivala S; Schaub Clerigué A; Speer T; Breitenstein A; Manz J; Lohmann C; Paneni F; Beer JH; Lüscher TF
[Ad] Endereço:Center for Molecular Cardiology, University of Zurich, Winterthurerstr. 190, CH-8057 Zurich, Switzerland.
[Ti] Título:Endothelial LOX-1 activation differentially regulates arterial thrombus formation depending on oxLDL levels: role of the Oct-1/SIRT1 and ERK1/2 pathways.
[So] Source:Cardiovasc Res;113(5):498-507, 2017 Apr 01.
[Is] ISSN:1755-3245
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Aims: The lectin-like oxLDL receptor-1 (LOX-1) promotes endothelial uptake of oxidized low-density lipoprotein (oxLDL) and plays an important role in atherosclerosis and acute coronary syndromes (ACS). However, its role in arterial thrombus formation remains unknown. We investigated whether LOX-1 plays a role in arterial thrombus formation in vivo at different levels of oxLDL using endothelial-specific LOX-1 transgenic mice (LOX-1TG) and a photochemical injury thrombosis model of the carotid artery. Methods and results: In mice fed a normal chow diet, time to arterial occlusion was unexpectedly prolonged in LOX-1TG as compared to WT. In line with this, tissue factor (TF) expression and activity in carotid arteries of LOX-1TG mice were reduced by half. This effect was mediated by activation of octamer transcription factor 1 (Oct-1) leading to upregulation of the mammalian deacetylase silent information regulator-two 1 (SIRT1) via binding to its promoter and subsequent inhibition of NF-κB signaling. In contrast, intravenous injection of oxLDL as well as high cholesterol diet for 6 weeks led to a switch from the Oct-1/SIRT1 signal transduction pathway to the ERK1/2 pathway and in turn to an enhanced thrombotic response with shortened occlusion time. Conclusions: Thus, LOX-1 differentially regulates thrombus formation in vivo depending on the degree of activation by oxLDL. At low oxLDL levels LOX-1 activates the protective Oct-1/SIRT1 pathway, while at higher levels of the lipoprotein switches to the thrombogenic ERK1/2 pathway. These findings may be important for arterial thrombus formation in ACS and suggest that SIRT1 may represent a novel therapeutic target in this context.
[Mh] Termos MeSH primário: Coagulação Sanguínea
Artérias Carótidas/enzimologia
Lesões das Artérias Carótidas/enzimologia
Lipoproteínas LDL/metabolismo
Proteína Quinase 1 Ativada por Mitógeno/metabolismo
Proteína Quinase 3 Ativada por Mitógeno/metabolismo
Fator 1 de Transcrição de Octâmero/metabolismo
Receptores Depuradores Classe E/metabolismo
Sirtuína 1/metabolismo
Trombose/enzimologia
[Mh] Termos MeSH secundário: Animais
Sítios de Ligação
Lesões das Artérias Carótidas/sangue
Lesões das Artérias Carótidas/genética
Colesterol na Dieta
Modelos Animais de Doenças
Predisposição Genética para Doença
Seres Humanos
Masculino
Camundongos Endogâmicos C57BL
Camundongos Transgênicos
NF-kappa B/genética
NF-kappa B/metabolismo
Fator 1 de Transcrição de Octâmero/genética
Fenótipo
Fosforilação
Regiões Promotoras Genéticas
Receptores Depuradores Classe E/genética
Transdução de Sinais
Sirtuína 1/genética
Tromboplastina/metabolismo
Trombose/sangue
Trombose/genética
Trombose/prevenção & controle
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cholesterol, Dietary); 0 (Lipoproteins, LDL); 0 (NF-kappa B); 0 (Octamer Transcription Factor-1); 0 (Olr1 protein, mouse); 0 (Pou2f1 protein, mouse); 0 (Scavenger Receptors, Class E); 0 (oxidized low density lipoprotein); 9035-58-9 (Thromboplastin); EC 2.7.11.24 (Mapk1 protein, mouse); EC 2.7.11.24 (Mitogen-Activated Protein Kinase 1); EC 2.7.11.24 (Mitogen-Activated Protein Kinase 3); EC 3.5.1.- (Sirt1 protein, mouse); EC 3.5.1.- (Sirtuin 1)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171010
[Lr] Data última revisão:
171010
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170216
[St] Status:MEDLINE
[do] DOI:10.1093/cvr/cvx015


  10 / 790 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28178663
[Au] Autor:Geier A; Macias RI; Bettinger D; Weiss J; Bantel H; Jahn D; Al-Abdulla R; Marin JJ
[Ad] Endereço:Division of Hepatology, Department of Medicine II, University Hospital Würzburg, Würzburg, Germany.
[Ti] Título:The lack of the organic cation transporter OCT1 at the plasma membrane of tumor cells precludes a positive response to sorafenib in patients with hepatocellular carcinoma.
[So] Source:Oncotarget;8(9):15846-15857, 2017 Feb 28.
[Is] ISSN:1949-2553
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Sorafenib is the drug of choice in the treatment of advanced hepatocellular carcinoma (HCC). Beneficial effects are limited by mechanisms of chemoresistance, which include downregulation and/or impaired function of plasma membrane transporters accounting for drug uptake. The organic cation transporter 1 (OCT1) plays a major role in sorafenib uptake and decreased expression in HCC has been associated with poorer response. METHODS: The multicenter retrospective TRANSFER study involved tumor biopsies from 39 patients with advanced HCC and sorafenib therapy for ≥4 wk. Endpoint was the relationship between clinicopathological features and immunohistological result. Immunostaining was performed using specific primary anti-OCT1-head and anti-OCT1-tail antibodies. Tumors were classified according to a simplified staining score as absent, weak, moderate or strong, taking into account the localization of the staining at the plasma membrane as positive or negative. RESULTS: Results confirmed OCT1 downregulation in half of the cases investigated (10% absent, 38% weak). However, only one third of tumors expressing OCT1 displayed plasma membrane location (15% vs. 36% cytosolic expression). When comparing HCC with and without OCT1 expression, no different sorafenib response was found. When tumors expressing OCT1 at the plasma membrane were considered separately, a marked longer survival was found (Log Rank p<0.001). No association between OCT1 expression at the plasma membrane with tumor stage, previous treatment with TACE or radiological response was seen.In conclusion, these results indicate that the presence of OCT1 at the plasma membrane, rather than its expression levels, is related to better outcome of HCC patients treated with sorafenib.
[Mh] Termos MeSH primário: Carcinoma Hepatocelular/tratamento farmacológico
Neoplasias Hepáticas/tratamento farmacológico
Niacinamida/análogos & derivados
Fator 1 de Transcrição de Octâmero/metabolismo
Compostos de Fenilureia/uso terapêutico
Inibidores de Proteínas Quinases/uso terapêutico
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Carcinoma Hepatocelular/metabolismo
Carcinoma Hepatocelular/patologia
Membrana Celular/metabolismo
Feminino
Seres Humanos
Neoplasias Hepáticas/metabolismo
Neoplasias Hepáticas/patologia
Masculino
Meia-Idade
Niacinamida/farmacocinética
Niacinamida/uso terapêutico
Fator 1 de Transcrição de Octâmero/deficiência
Compostos de Fenilureia/farmacocinética
Inibidores de Proteínas Quinases/farmacocinética
Estudos Retrospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Octamer Transcription Factor-1); 0 (POU2F1 protein, human); 0 (Phenylurea Compounds); 0 (Protein Kinase Inhibitors); 25X51I8RD4 (Niacinamide); 9ZOQ3TZI87 (sorafenib)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170922
[Lr] Data última revisão:
170922
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170209
[St] Status:MEDLINE
[do] DOI:10.18632/oncotarget.15029



página 1 de 79 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde